Darovasertib (LXS-196, NVP-LXS196, IDE196)
$150.00 – $900.00
Darovasertib (CAS No.: 1874276-76-2), is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. Darovasertib has the potential for uveal melanoma research. >98% Purity.
Synonyms: LXS-196, IDE-196, LXS196, IDE196, protein kinase C inhibitor, PKC inhibitor
For Research Use Only.
- Product Details
- Description
- Additional information
- More Offers
Description
APIM050045: Darovasertib (LXS-196, IDE-196) is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. Darovasertib has the potential for uveal melanoma research.
CAS No.: 1874276-76-2
IUPAC/Chemical Name: 3-amino-N-(3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl)-6-(3-(trifluoromethyl)pyridin-2-yl)pyrazine-2-carboxamide
Molecular Formula: C22H23F3N8O
Molecular Weight: 472.48
Purity: 99.9% by HPLC
QC: Achiral and Chiral HPLCs, MS, NMR, and Quantitative Elemental Analysis Report
Solubility: Soluble in DMSO
Storage: Dry, dark and at 0 – 4 C for short term (days to weeks) or -20 C for long term (months to years).
Note: Please contact us for COA, Spectra, and SDS information.
Background Information:
Uveal melanoma (UM) is the most common primary intraocular tumor. The majority (>90%) of uveal melanoma harbor activating mutations in the GNAQ and GNA11 Ga subunits of G protein coupled receptors. These genetic driver mutations, which are also detected in other solid tumors, lead to continuous activation of protein kinase C (PKC) and downstream signaling pathways such as the mitogen-activated protein kinase (MAPK) signaling pathway. Inhibition of PKC with small molecule inhibitors is an attractive therapeutic approach in UM. Darovasertib (LXS-196, IDE-196) is a selective and potent protein kinase C inhibitor targeting the novel (δ, ε, η, θ) and classical (α, β) PKC isoforms and has shown anti-tumor activity as monotherapy in patients with metastatic uveal melanoma (MUM). Inhibiting downstream signaling pathways in addition to PKC inhibition with Darovasertib (LXS-196, IDE-196) may increase the anti-tumor activity in MUM patients. Modulation of PKC, MAPK pathway activity and other downstream markers were assessed by WB. The evaluated uveal melanoma cell lines expressed different phospho-PKC isoforms and were sensitive to increasing concentrations of Darovasertib (LXS-196, IDE-196) as demonstrated by decreased levels of PKC substrate p-MARCKS and reduced cell viability. Combination of Darovasertib (LXS-196, IDE-196) with MEK inhibitors Binimetinib or Trametinib showed synergy at clinically relevant doses for each compound. The observed synergy of Darovasertib (LXS-196, IDE-196) with MEK inhibitors is further substantiated by modulation of MARCKS and MAPK pathway activity as measured by WB.
Target: PKCα, PKCθ, GSK3β
IC50: 1.9 nM (PKCα), 0.4 nM (PKCθ), 3.1 μM (GSK3β)
In Vitro: Upon oral administration, protein kinase C inhibitor Darovasertib (LXS-196) binds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival. [1]
In Vivo: Darovasertib (LXS-196) (15, 30, 75, 150 mg/kg, P.O., mice) shows improved efficacy (regression) in a 92.1 GNAQ uveal melanoma xenograft model in a dose-dependently manner. [1]
What is the solubility of Darovasertib (LXS-196) (CAS No. 1874276-76-2) in vitro?
DMSO: > 25 mg/mL
What is the solubility of Darovasertib (LXS-196) (CAS No. 1874276-76-2) in vivo?
1. DMSO, PEG300, Tween-80, and saline
Please add 10% DMSO, 40% PEG300, 5% Tween-80, and 45% saline in order, solubility: ≥ 2.5 mg/mL.
2. DMSO and 20% SBE-β-CD in saline
Please add 10% DMSO and 90% (20% SBE-β-CD in saline) in order, solubility: ≥ 2.5 mg/mL.
3. DMSO and corn oil
Please add 10% DMSO and 90% corn oil in order, solubility: ≥ 2.5 mg/mL.
Reference:
[1]. Frey, C. R. et al. “Abstract 5337: Analysis of drug combinations with the PKC inhibitor IDE196 support dual MEK and PKC inhibition as a rational combination in metastatic uveal melanoma”, Cancer Res., 2020, DOI: 10.1158/1538-7445.AM2020-5337.
[2]. Shoushtari, A. N. et al. “A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma”, Cancers (Basel), 2021, 13, 5504. doi: 10.3390/cancers13215504.
Frequent questions related to “Darovasertib (LXS-196, IDE-196) (CAS No. 1874276-76-2), a potent, selective and orally active protein kinase C (PKC) inhibitor”:
Does Darovasertib bind mouse PKC?
Does Darovasertib bind mouse protein kinase C?
Who makes Darovasertib?
What is Darovasertib?
What is the mechanism of action for Darovasertib?
Popular searches related to “Darovasertib (LXS-196, IDE-196) (CAS No. 1874276-76-2), a potent, selective and orally active protein kinase C (PKC) inhibitor”:
Darovasertib results
Darovasertib fda approval
Darovasertib mechanism of action
Darovasertib price
Darovasertib synthesis
Darovasertib analogue
Darovasertib structure activity study
Darovasertib in vitro
Darovasertib in vivo
Darovasertib supplier
Darovasertib clinical study
Darovasertib Cytotoxicity
Darovasertib Target
Darovasertib PKC inhibitor
Darovasertib purchase
Darovasertib protein kinase C inhibitor
Additional information
| Size | 10 mg, 100 mg, 5 mg, 50 mg |
|---|
